Cited by 1,021SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 epidemiological studies

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Open access

Ibarrondo, F. Javier, Fulcher, Jennifer A., Goodman-Meza, David, Elliott, Julie, Hofmann, Christian, Hausner, Mary A., Ferbas, Kathie G., Tobin, Nicole H., Aldrovandi, Grace M., Yang, Otto O.·2020·New England Journal of Medicine

DOI 10.1056/nejmc2025179PMC PMC7397184

Open this paper in CoChat — free account

Abstract

Covid-19 Antibodies after Mild Infection Among 34 volunteers who had recovered from mild Covid-19 illness, antiviral antibodies to the receptor-binding domain of the viral spike protein declined wi...

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmc2025179

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup
Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Roubidoux, E. K., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 635
Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367
Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A Virus
Andraud, M., Lejeune, O., Musoro, J. Z., Ogunjimi, B., Beutels, P., & Hens, N. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002418 · Cited by 75
Longitudinal Analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus-Specific Antibody in SARS Patients
Chang, S., Wang, J., Huang, L., Chen, Y., Fang, C., Sheng, W., Wang, J., Yu, C., & Yang, P. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.12.1455-1457.2005 · Cited by 32

Flagged first, then by citations

Show all 5 references

Sorted by citations

Items 601–700 of 1,002

Longitudinal evaluation of the Abbott ARCHITECT SARS-CoV-2 IgM and IgG assays in a pediatric population
Interiano, C., Muze, S., Turner, B., Gonzalez, M. D., Rogers, B. B., Jerris, R. C., Weinzierl, E. P., Elkhalifa, M. A., & Leung‐Pineda, V. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00208 · Cited by 8
Epidemiology and clinical evolution of non-multisystem inflammatory syndrome (MIS-C) dermatological lesions in pediatric patients affected by SARS-CoV-2 infection: A systematic review of the literature
Dondi, A., Sperti, G., Gori, D., Guaraldi, F., Montalti, M., Parini, L., Piraccini, B. M., Lanari, M., & Neri, I. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04585-7 · Cited by 9
Anti-SARS-CoV-2 IgM and IgG antibodies in health workers in Sergipe, BrazilPreprint
Seabra, M. S. D. M., Borges, L. P., de Souza, D. R. V., Martins, A. F., Neto, J. M. D. R., Ribeiro, A. A., Santos, A. A., da Invenção, G. B., Matos, I. L. S., dos Santos, K. A., et al. (2020) · medRxiv · doi:10.1101/2020.09.24.20200873 · Cited by 8
Anti-SARS-CoV-2 Serology persistence over time in COVID-19 Convalescent Plasma DonorsPreprint
Giorgi, V. D., West, K. A., Henning, A. N., Chen, L., Holbrook, M. R., Gross, R., Liang, J. Y., Postnikova, E. N., Trenbeath, J. L., Pogue, S., et al. (2021) · medRxiv · doi:10.1101/2021.03.08.21253093 · Cited by 8
Autonomic conditioning therapy reduces fatigue and improves global impression of change in individuals with post-acute COVID-19 syndromePreprint
Putrino, D. F., TABACOF, L. R., Tosto-Mancuso, J. M., Wood, J., Cortes, M., Kontorovich, A., McCarthy, D., Breyman, E., Nasr, L., Neglia, A., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-440909/v1 · Cited by 8
Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report
Massanella, M., Martín-Urda, A., Mateu, L., Marín, T., Aldás, I., Riveira‐Muñoz, E., Kipelainen, A., Jiménez‐Moyano, E., de la Concepción, M. L. R., Ávila‐Nieto, C., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab329 · Cited by 7
Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in Lebanon: a population-based cross-sectional study
Mahdi, A., Khazen, G., Aziz, N., Mina, J., Papazian, A., Daou, L., Ahmar, J., Assaf, N., Abdulkhalek, A., Farhat, H. Z., et al. (2022) · IJID Regions · doi:10.1016/j.ijregi.2022.01.011 · Cited by 7
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity
van Dam, K. P. J., Volkers, A., Wieske, L., Stalman, E. W., Kummer, L. Y. L., van Kempen, Z. L. E., Killestein, J., Tas, S. W., Boekel, L., Wolbink, G., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08298-6 · Cited by 7
Guardians of immunity: NK cell-mediated defense in COVID-19 and post-COVID scenarios
Петров, С. В., Taskov, H. B., & Murdjeva, M. (2024) · Folia Medica · doi:10.3897/folmed.66.e113356 · Cited by 7
SARS-COV-2, can you be over it?
Fiocchi, A., & Jensen-Jarolim, E. (2021) · The World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100514 · Cited by 6
Assessment of SARS-CoV-2 Infection among Healthcare Workers of a German COVID-19 Treatment Center
Larribère, L., Gordejeva, J., Kuhnhenn, L., Kurscheidt, M., Pobiruchin, M., Vladimirova, D., Martin, M., Roser, M., Schramm, W., Martens, U. M., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18137057 · Cited by 7
Impact of Prior Infection on Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Syrian Hamsters
Zhang, C., Guo, Z., Li, N., Cui, H. Y., Meng, K., Liu, L., Zhao, L., Zhang, S., Qin, C., Liu, J., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.722178 · Cited by 8
SARS-CoV-2 seroprevalence in healthcare workers of a teaching hospital in a highly endemic region in the Netherlands after the first wave: a cross-sectional study
Bouwman, M. M. A., van Osch, F., Crijns, F. R. L., Trienekens, T. A. M., Mehagnoul-Schipper, J., van den Bergh, J. P., & de Vries, J. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-051573 · Cited by 7
Cytidine deamination-induced perpetual immunity to SAR-CoV-2 infection is a potential new therapeutic target
Ullah, A., Mabood, N., Maqbool, M., Khan, L., & Ullah, M. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.61779 · Cited by 7
Demographic and Clinical Factors Associated with Reactivity of Anti-SARS-CoV-2 Antibodies in Serbian Convalescent Plasma Donors
Grujić, J., Bujandrić, N., Budakov-Obradović, Z., Dolinaj, V., Bogdan, D., Savić, N., Cabezas‐Cruz, A., Mijatović, D., Simin, V., Anđelić, N., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19010042 · Cited by 8
SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India
Chunchu, S. R., Ravula, U., Gente, V. K., Bacchu, S., Rao, S. P. R., & Mooli, S. (2022) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-021-01512-y · Cited by 7
Analysis of accumulated SARS-CoV-2 seroconversion in North Carolina: The COVID-19 Community Research Partnership
Williamson, J., Wierzba, T. F., Santacatterina, M., Munawar, I., Seals, A. L., Ballard, C. A. P., Alexander‐Miller, M. A., Runyon, M. S., McCurdy, L., Gibbs, M. A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0260574 · Cited by 7
SARS-CoV-2-Induced Immunosuppression: A Molecular Mimicry Syndrome
Kanduc, D. (2022) · Global Medical Genetics · doi:10.1055/s-0042-1748170 · Cited by 7
Early SARS-CoV-2 dynamics and immune responses in unvaccinated participants of an intensely sampled longitudinal surveillance study
Gunawardana, M., Webster, S., Rivera, S., Cortez, J. M., Breslin, J., Pinales, C., Buser, C., Ibarrondo, F. J., Yang, O. O., Bobardt, M. D., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00195-4 · Cited by 9
Self-citation
Efficacy of COVID-19 Vaccination in People Living with HIV: A Public Health Fundamental Tool for the Protection of Patients and the Correct Management of Infection
Facciolà, A., D’Amato, S., Calimeri, S., Giudice, D. L., Micali, C., Russotto, Y., Rullo, E. V., Nunnari, G., Squeri, R., & Pellicanò, G. F. (2022) · Infectious Disease Reports · doi:10.3390/idr14050080 · Cited by 7
COVID-19 Health Passes: Practical and Ethical Issues
Millán, G. M. O. (2023) · Journal of Bioethical Inquiry · doi:10.1007/s11673-022-10227-2 · Cited by 8
Evaluation of humoral immune response in relation to COVID-19 severity over 1 year post-infection: critical cases higher humoral immune response than mild cases
Bang, M.-S., Kim, C., Cho, N., Seo, J.-W., Kim, D. Y., Yun, N. R., & Kim, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203803 · Cited by 7
Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison
Kroidl, I., Winter, S., Rubio‐Acero, R., Bakuli, A., Geldmacher, C., Eser, T. M., Deák, F., Horn, S., Zielke, A., Ahmed, M. I. M., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02167-z · Cited by 7
SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
Ameratunga, R., Jordan, A., Lehnert, K., Leung, E. Y., Mears, E., Snell, R. G., Steele, R., & Woon, S. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105894 · Cited by 8
Indicators of the Immune Status in Children after a New Coronavirus Infection
Москалева, Е. В., Петрова, А. Г., Rychkova, L. V., Novikova, E. A., & Vanyarkinа, A. S. (2021) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2021-6.2.6 · Cited by 7
Antibody Responses to SARS-CoV-2 Infection—Comparative Determination of Seroprevalence in Two High-Throughput Assays versus a Sensitive Spike Protein ELISA
Mohanraj, D., Whitelegg, A. M. E., Bicknell, K., Bhole, M., Taylor, L., & Webber, C. (2021) · Vaccines · doi:10.3390/vaccines9111310 · Cited by 6
Prevalence of current and past COVID-19 in Ohio adults
Turner, A. N., Kline, D., Norris, A. H., Phillips, W. G., Root, E. D., Wakefield, J. C., Li, Z., Lemeshow, S. A., Spahnie, M., Luff, A., et al. (2021) · Annals of Epidemiology · doi:10.1016/j.annepidem.2021.11.009 · Cited by 7
A sero-epidemiological study after two waves of the COVID-19 epidemic
Raheem, R. A., Moosa, S., Waheed, F., Aboobakuru, M., Ahmed, I. N., Rafeeg, F. N., & Saeed, M. (2022) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-040721-1177 · Cited by 5
Investigation and long‐term monitoring of the presence of neutralizing antibody in patients with COVID‐19 disease of different clinical severity
Kaygusuz, S., Korukluoğlu, G., Coşgun, Y., Şahin, Ö., & Arslan, F. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27751 · Cited by 8
COVID-19 Antibody Detection and Assay Performance Using Red Cell Agglutination
Srivastava, K., West, K. A., Giorgi, V. D., Holbrook, M. R., Bovin, N. V., Henry, S. M., & Flegel, W. A. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00830-21 · Cited by 7
Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugal—A Multicenter, Nationwide Study
Cruz-Machado, A. R., Barreira, S. C., Bandeira, M., Veldhoen, M., Gomes, A., Serrano, M., Duarte, C., Rato, M., Fernandes, B. M., Garcia, S., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.901817 · Cited by 7
A longitudinal follow-up of COVID-19 patients in the convalescent phase showed recovery in radiological results, the dynamics of lymphocytes, and a decrease in the level of IgG antibody: a single-centre, observational study
Wang, Z., Yang, L., Chen, Y., Xu, Z., Wang, H., & Zhang, X. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3011 · Cited by 7
Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous Dendritic Cells from Patients Previously Infected with SARS-CoV-2Preprint
Sieling, P. A., Zakin, L., Shin, A., Morimoto, B., Adisetiyo, H., Garbán, H., Liu, P., Rice, A., Taft, J. D., Patel, R. S., et al. (2020) · medRxiv · doi:10.1101/2020.11.04.20225417 · Cited by 7
Development and longevity of antibodies against SARS‐CoV‐2 in kidney transplant recipients after symptomatic COVID‐19
Bajpai, D., Shah, D., Bose, S., Deb, S., Gandhi, C., Modi, T., Rao, N., Kumar, K., Saxena, N., Katyal, A., et al. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13646 · Cited by 7
Boosting with adjuvanted SCB-2019 elicits superior Fcγ-receptor engagement driven by IgG3 to SARS-CoV-2 spike
Jung, W., Yuan, D., Kellman, B. P., Gonzalez, I. G. D. S., Clemens, R. L., Milan, E. P., Sprinz, E., Cerbino-Neto, J., Smolenov, I. V., Alter, G., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00791-y · Cited by 6
Serological evidence of sarbecovirus exposure along Sunda pangolin trafficking pathways
Worthington, B. M., Wong, P. Y.-H., Kumaree, K. K., Prigge, T., Ng, K. H., Liao, Y., Martelli, P. R., Churgin, S. M., Lee, F. K., Perkins, C., et al. (2024) · BMC Biology · doi:10.1186/s12915-024-02074-x · Cited by 6
Symptomatic recurrence of SARS-CoV-2 infection in healthcare workers recovered from COVID-19
Atıcı, S., Ek, Ö. F., Yıldız, M. S., Şıkgenç, M. M., Güzel, E., & Soysal, A. (2021) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.14305 · Cited by 6
Modeling of the COVID-19 pandemic in the limit of no acquired immunity
Ilnytskyi, J. (2021) · Mathematical Modeling and Computing · doi:10.23939/mmc2021.02.282 · Cited by 6
Impact of chemotherapy and immunotherapy on the composition and function of immune cells in COVID-19 convalescent with gynecological tumors
Qin, T., Guo, E., Lu, F., Fu, Y., Liu, S., Xiao, R., Wu, X. Y., Liu, C., He, C., Wang, Z., et al. (2021) · Aging · doi:10.18632/aging.203739 · Cited by 6
Vaccine Development Should Be Polytheistic, Not Monotheistic
Plotkin, S. A., Robinson, J. M., Fitchett, J. R. A., & Gershburg, E. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae460 · Cited by 6
Extracción y caracterización química del aceite esencial de Eucalipto obtenido por microondas y ultrasonido
Universidad Nacional Agraria La Molina, L.-P., Cama, D. N., Villanueva-Quejia, E., Universidad Nacional Agraria La Molina, L.-P., Sakoda, B. H., Universidad Nacional Agraria La Molina, L.-P., Monzón, L. A. T., & Universidad Nacional Agraria La Molina, L.-P. (2020) · Revista de Investigaciones Altoandinas - Journal of High Andean Research · doi:10.18271/ria.2020.661 · Cited by 6
Sustained seroprevalence of SARS-CoV-2 antibodies one year after infection: one of the first COVID-19 cluster cases in Bosnia and Herzegovina
Šušak, B., Mikulić, V., Lazarević, A., Mikulić, I., & Arapović, J. (2021) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2021.6340 · Cited by 6
Dynamical Analysis of Universal Masking on the Pandemic
Kaiheng, B. T., Roby, C. A., Wu, J. W., & Tan, D. Y. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18179027 · Cited by 6
Prevalencia de anticuerpos contra el SARS-CoV-2 según el estatus socioeconómico y étnico en una encuesta nacional de Brasil
Horta, B. L., da Silveira, M. F., Barros, A. J. D., Barros, F. C., Hartwig, F. P., Dias, M. D. S., Menezes, A. M. B., Hallal, P. C., & Victora, C. G. (2021) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2021.105 · Cited by 7
Biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the humoral immunoresponse: a systematic review of evidence to support global policy-level actions and research
Nair, S., & Chen, X. (2021) · Global Health Journal · doi:10.1016/j.glohj.2021.11.005 · Cited by 6
The immunologic response to severe acute respiratory syndrome coronavirus 2
Le, N. K., Kaman, K., Martin, H. C., Mullur, J., Stenehjem, K. K., Coomar, L. A., Bahar, B., Dutta, M., Izurieta, R., & Brooks, J. P. (2021) · Allergy and Asthma Proceedings · doi:10.2500/aap.2021.42.210077 · Cited by 6
BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
Kaznadzey, A., Tutukina, M. N., Bessonova, T. A., Kireeva, M. L., & Mazo, I. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.797918 · Cited by 6
Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up
Adriaenssens, N., Scholtes, B., Bruyndonckx, R., Ngoc, P. V., Verbakel, J. Y. J., Sutter, A. D., Heytens, S., den Bruel, A. V., Desombere, I., Damme, P. V., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-065897 · Cited by 7
Can Probiotics, Particularly Limosilactobacillus fermentum UCO-979C and Lacticaseibacillus rhamnosus UCO-25A, Be Preventive Alternatives against SARS-CoV-2?
Valdebenito-Navarrete, H., Fuentes-Barrera, V., Smith, C. T., Salas-Burgos, A., Zuñiga, F. A., Gómez, L. A., & García, A. (2023) · Biology · doi:10.3390/biology12030384 · Cited by 7
Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19
Barrios, M. H., Nicholson, S. R., Bull, R. A., Martinello, M., Rawlinson, W. D., Mina, M., Post, J. J., Hudson, B. J., Gilroy, N. M., Lloyd, A. R., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11081985 · Cited by 4
The correlation between humoral immune responses and severity of clinical symptoms in COVID-19 patients
Akbarian, S., Sheikhi, M., Khedri, P., Baharifar, N., Shamsabadi, F. K., Davidi, M. R., Khazaei, H. A., Assarian, H., & Sheikhi, A. (2023) · Epidemiology and Infection · doi:10.1017/s0950268823001437 · Cited by 6
The Evolution of Serological Assays during Two Years of the COVID-19 Pandemic: From an Easy-to-Use Screening Tool for Identifying Current Infections to Laboratory Algorithms for Discovering Immune Protection and Optimizing Vaccine Administration
Nicolai, E., Tomassetti, F., Pignalosa, S., Redi, S., Marino, M., Basile, U., & Ciotti, M. (2024) · COVID · doi:10.3390/covid4080091 · Cited by 7
Significant reduction of humoral response to SARS-CoV-2 4 months after the diagnosis of COVID-19
Zhang, K., Ma, Z., Yang, L., Kang, W., Yin, Y., & Lau, J. Y. (2020) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaa036 · Cited by 8
The chemical biology of coronavirus host–cell interactions
Datta, S., Hett, E. C., Vora, K. A., Hazuda, D. J., Oslund, R., Fadeyi, O., & Emili, A. (2020) · RSC Chemical Biology · doi:10.1039/d0cb00197j · Cited by 6
Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS-CoV-2
Valk, S. J., Piechotta, V., Kimber, C., Chai, K. L., Monsef, I., Doree, C. J., Wood, E. M., Lamikanra, A., Roberts, D. J., McQuilten, Z., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013802 · Cited by 6
Immunological Response to SARS-CoV-2 Is Sustained by Vitamin D: A Case Presentation of One-Year Follow-Up
Luciani, F., Caroleo, M. C., Cannataro, R., Mirra, D., D’Agostino, B., Gallelli, L., & Cione, E. (2021) · Reports — Medical Cases Images and Videos · doi:10.3390/reports4020018 · Cited by 6
SARS-CoV-2 seroprevalence among employees of a university hospital in Belgium during the 2020 COVID-19 outbreak (COVEMUZ-study)
Geyter, D. D., Vancutsem, E., Laere, S. V., Piérard, D., Lacor, P., Weets, I., & Allard, S. D. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821001540 · Cited by 6
Longitudinal COVID-19 Surveillance and Characterization in the Workplace with Public Health and Diagnostic Endpoints
Gunawardana, M., Breslin, J., Cortez, J. M., Rivera, S., Webster, S., Ibarrondo, F. J., Yang, O. O., Pyles, R. B., Ramirez, C. M., Adler, A. P., et al. (2021) · mSphere · doi:10.1128/msphere.00542-21 · Cited by 6
Self-citation
Decline in Sars‐CoV‐2 antibodies over 6‐month follow‐up in obstetrical healthcare workers
Kiefer, M. K., Allen, K. D., Russo, J. R., Ma’ayeh, M., Gee, S. E., Kniss, D. A., Cackovic, M., Costantine, M. M., & Rood, K. M. (2021) · American Journal of Reproductive Immunology · doi:10.1111/aji.13490 · Cited by 6
Half-Year Longitudinal Seroprevalence of SARS-CoV-2-Antibodies and Rule Compliance in German Hospital Employees
Herzberg, J., Vollmer, T., Fischer, B., Becher, H., Becker, A., Sahly, H., Honarpisheh, H., Guraya, S. Y., Strate, T. G., & Knabbe, C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182010972 · Cited by 6
Surrogate test performance for SARS‐CoV ‐2 neutralizing antibodies ( nAbs ) for convalescent plasma ( CCP ): How useful could they be?
Wendel, S., Fachini, R. M., Fontão‐Wendel, R., Mello, R., Velasquez, C. V., Machado, R. R. G., Brito, M., Amaral, M., Soares, C. P., Achkar, R., et al. (2021) · Transfusion · doi:10.1111/trf.16714 · Cited by 6
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials
Lim, H. Y., Arip, M., Yahaya, A. A. A.-F. B., Jazayeri, S. D., Poppema, S., & Poh, C. L. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/5024 · Cited by 6
Patient and Clinical Factors at Admission Affect the Levels of Neutralizing Antibodies Six Months after Recovering from COVID-19
Li, X., Pang, L., Yin, Y., Zhang, Y., Xu, S., Xu, D., & Shen, T. (2022) · Viruses · doi:10.3390/v14010080 · Cited by 6
Seropositivity of SARS‐CoV‐2 IgG Antibody among People in Dhaka City during the Prevaccination Period
Ahmed, Z. B., Razu, M. H., Akter, F., Rabby, M. R. I., Karmaker, P., & Khan, M. (2022) · BioMed Research International · doi:10.1155/2022/4451144 · Cited by 6
A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students
Lee, C. C., Segaloff, H. E., Cole, D., Rosenblum, H. G., Morgan, C. N., Somers, T. S., Desamu-Thorpe, R., Foster, M. A., Currie, D. W., Ruff, J. C., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07314-5 · Cited by 7
Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration
de Oliveira, C. F., Neto, W. F. F., da Silva, C. P., Ribeiro, A. C. D. S., Martins, L. C., de Sousa, A. W., Freitas, M. N. O., Chiang, J. O., Silva, F. A., dos Santos, É. B., et al. (2022) · Vaccines · doi:10.3390/vaccines10050690 · Cited by 6
COVID-19 morbidity in Afghanistan: a nationwide, population-based seroepidemiological study
Saeedzai, S. A., Sahak, M. N., Arifi, F., Aly, E., van Gurp, M., White, L. J., Chen, S., Barakat, A., Azim, G., Rasoly, B., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060739 · Cited by 6
Chest pain mimicking pulmonary embolism may be a common presentation of COVID‐19 in ambulant patients without other typical features of infection
Harrison, S. R., Klassen, J. R. L., Bridgewood, C., Scarsbrook, A. F., Marzo‐Ortega, H., & McGonagle, D. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13267 · Cited by 6
Comparison of Immunogenicity and Safety between a Single Dose and One Booster Trivalent Inactivated Influenza Vaccination in Patients with Chronic Kidney Disease: A 20-Week, Open-Label Trial
Chang, Y., Ling, T., Cheng, Y., Sun, C., Wu, J.-L., Tai, C.-H., Wang, J., & Sung, J. (2021) · Vaccines · doi:10.3390/vaccines9030192 · Cited by 6
Salivary testing of COVID-19: evaluation of serological testing following positive salivary results
Caulley, L., Shaw, J. L. V., Corsten, M. J., Hua, N., Angel, J. B., Poliquin, G., Whelan, J. R., Antonation, K. S., & Johnson‐Obaseki, S. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06108-5 · Cited by 6
Clinical Evaluation of a COVID-19 Antibody Lateral Flow Assay using Point of Care SamplesPreprint
Lee, W., Straube, S., Sincic, R. S., Noble, J., Montoy, J. C. C., Kornblith, A. E., Prakash, A., Wang, R. C., Bainton, R. J., & Kurien, P. A. (2020) · medRxiv · doi:10.1101/2020.12.02.20242750 · Cited by 5
ROS/RNS balancing, aerobic fermentation regulation and cell cycle control – a complex early trait (‘CoV-MAC-TED’) for combating SARS-CoV-2-induced cell reprogrammingPreprint
Costa, J. H., Mohanapriya, G., Bharadwaj, R., Noceda, C., Thiers, K. L. L., Aziz, S., Srivastava, S., Oliveira, M., Gupta, K. J., Kumari, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.08.447491 · Cited by 6
SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recencyPreprint
Takahashi, S., Peluso, M. J., Hakim, J. M. C., Turcios, K., Janson, O., Routledge, I., Busch, M. P., Hoh, R., Tai, V., Kelly, J. D., et al. (2021) · medRxiv · doi:10.1101/2021.09.09.21263139 · Cited by 6
A single dose ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of double dose vaccinated SARS-CoV-2 infection naïve individualsPreprint
Gelanew, T. I., Mulu, A., Abebe, M., Bates, T. A., Wassie, L., Tefer, M., Fentahun, D., Alemu, A., Tamiru, F., Assefa, G., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1250175/v1 · Cited by 6
Influence of Prior SARS-CoV-2 Infection on COVID-19 Severity: Evidence from the National COVID Cohort CollaborativePreprint
Hendrix, N., Sidky, H., & Sahner, D. (2023) · medRxiv · doi:10.1101/2023.08.03.23293612 · Cited by 5
COVID-19 antibody responses in individuals with natural immunity and with vaccination-induced immunity: a systematic review and meta-analysis
Zhang, Q., Jiao, L., Chen, Q., Bulstra, C. A., Geldsetzer, P., de Oliveira, T., Yang, J., Wang, C., Bärnighausen, T., & Chen, S. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02597-y · Cited by 5
Post-acute sequelae of SARS-CoV-2 mimic: An important neurological condition
Ohira, M., Osada, T., Kimura, H. J., Sano, T., & Takao, M. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123199 · Cited by 5
Antibodies periodically wax and wane in survivors of Ebola
Woolsey, C. B., & Geisbert, T. W. (2021) · Nature · doi:10.1038/d41586-020-03044-3 · Cited by 5
The humoral immune response to SARS-CoV-2 mounts and is durable in symptomatic haemodialysis patients
Milia, V. L., Tonolo, S., Luzzaro, F., Bonato, C., Cavalli, A., Foglieni, B., Debiase, C., Limardo, M., Longhi, S., Ravasi, C., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab047 · Cited by 5
Humoral and cellular response in convalescent COVID-19 lupus patients
Solé, C., Domingo, S., Vidal, X., & Cortés-Hernández, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-17334-5 · Cited by 6
SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients – a comparative long term post-infection study
Brehm, J., Spaeth, A., Dreßler, L., Masetto, T., Dannenberg, R., Peter, C., & Grimmler, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915338 · Cited by 5
RETRACTED: The pathogenicity of COVID-19 and the role of pentraxin-3: An updated review study
Margiana, R., Sharma, S. K., Khan, B. I., Alameri, A. A., Opulencia, M. J. C., Hammid, A. T., Hamza, T. A., Хамракулович, Б. Ш., Abdelbasset, W. K., & Jawhar, Z. H. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154128 · Cited by 5
Retracted
Incidence and risk factors of SARS-CoV-2 infection among workers in a public health laboratory in Tunisia
Kharroubi, G., Cherif, I., Ghawar, W., Dhaouadi, N., Yazidi, R., Châabane, S., Snoussi, M. A., Salem, S., Hamouda, W. B., Hamouda, S. B., et al. (2023) · Archives of Virology · doi:10.1007/s00705-022-05636-y · Cited by 5
Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers
Mouna, L., Razazian, M., Duquesne, S., Roque‐Afonso, A., & Vauloup‐Fellous, C. (2023) · Viruses · doi:10.3390/v15020426 · Cited by 6
Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.S.
García‐Carreras, B., Hitchings, M. D. T., Johansson, M. A., Biggerstaff, M., Slayton, R. B., Healy, J. M., Lessler, J., Quandelacy, T. M., Salje, H., Huang, A. T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37944-5 · Cited by 5
The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2
Dhawan, M. K., Thakur, N., Sharma, M. K., & Rabaan, A. A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117936 · Cited by 5
COVID-19-Pandemie-bedingte Belastungen und SARS-CoV-2-Prävalenz in Pflegeeinrichtungen
Perkhofer, L., Grünke, P., Gashi-Ymeri, E., Grünke, T., Kroschel, J., Michel, D., Pensel, E., Rost, A., Denkinger, M. D., Dallmeier, D., et al. (2021) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-021-01931-6 · Cited by 5
The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal
Tosta, E. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00014 · Cited by 5
Comparison of SARS-CoV-2 variant lethality in human angiotensin-converting enzyme 2 transgenic mice
Lee, T. Y., Lee, H., Kim, N., Jeon, P., Kim, J., Lim, H., Yang, J., Kim, K.-C., & Lee, J.-Y. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198563 · Cited by 4
Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan
Hagihara, M., Ohara, S., Uchida, T., & Inoue, M. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03175-x · Cited by 5
A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects
de Boer, J., Saade, U., Granjon, E., Trouillet‐Assant, S., Saade, C., Pottel, H., Zrein, M. A., & Covid ser study group (2022) · PLoS ONE · doi:10.1371/journal.pone.0274553 · Cited by 6
Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection
Pidal, P., Fernández, J. O., Airola, C., Araujo, M., Menjiba, A. M., Martín, H. S., Bruneau, N., Balanda, M., Elgueta, C., Fasce, R., et al. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00753-6 · Cited by 5
Persistence of SARS-CoV-2 IgG Antibody Response among South African Adults: A Prospective Cohort Study
Adeniyi, O. V., Durojaiye, O. C., & Masilela, C. M. (2023) · Vaccines · doi:10.3390/vaccines11061068 · Cited by 5
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
Provencio, M., Rodríguez‐Abreu, D., Granados, A. L. O., Serrano, G., Aguado, C., Franco, F., Gutiérrez, V., López-Vivanco, G., Guirado, M., Benítez, G., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-504 · Cited by 5
Antibody Response to SARS-CoV-2 in Relation to the Contributing Factors in COVID-19 Patients
Aziz, H., Fatima, S., Mahmood, H., Muhammad, S., Saeed, M. A. R., Khurshid, S., Aslam, W., Aziz, S., & Faheem, M. (2022) · Viral Immunology · doi:10.1089/vim.2021.0097 · Cited by 5
Evaluation of Spike Protein Epitopes by Assessing the Dynamics of Humoral Immune Responses in Moderate COVID-19
Chen, L., Pang, P., Qi, H., Yan, K., Ren, Y., Ma, M., Cao, R., Li, H., Hu, C., Li, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.770982 · Cited by 5
Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus
Papaneophytou, C. P., Nicolaou, A., Pieri, M., Nicolaidou, V., Galatou, E., Sarigiannis, Y. M., Pantelidou, M., Panayi, P., Thoma, T., Stavraki, A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269885 · Cited by 6
The Impact of Age Demographics on Interpreting and Applying Population-Wide Infection Fatality Rates for COVID-19
MacLeod, M. R., & Hunter, D. G. (2021) · INFORMS Journal on Applied Analytics · doi:10.1287/inte.2020.1070 · Cited by 5
Prevalence of IgG antibodies induced by the SARS‐COV‐2 virus in asymptomatic adults in Nuevo Leon, Mexico
Vidales, E. P. R., Garza‐Carrillo, D., Perez‐Trujillo, J. J., Robles‐Rodríguez, O. A., Salinas-Martı́nez, A. M., Montes‐de‐Oca‐Luna, R., Treviño‐Garza, C., & de la O-Cavazos, M. E. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27131 · Cited by 5
Letter to the Editor: The Interpretation of COVID-19 Seroprevalence Study Should Be Cautious
Lee, J., Kim, S. Y., Sung, H., Choe, Y. J., & Hong, K. H. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e338 · Cited by 5

Authors: Ibarrondo, F. J., Fulcher, J. A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M. A., Ferbas, K. G., Tobin, N. H., Aldrovandi, G. M., & Yang, O. O.
Affiliations: University of California, Los Angeles (US)
David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA
Corresponding author: Yang, Otto O.
ORCID: Ibarrondo, F. Javier
Fulcher, Jennifer A.
Hofmann, Christian
Ferbas, Kathie G.
Tobin, Nicole H.
Aldrovandi, Grace M.
Yang, Otto O.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-09-10
Volume: 383
Issue: 11
Pages: 1085-1087
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmc2025179
PMC: PMC7397184
OpenAlex: W3044311014
Cited by: 1,021
References: 5
Citations by year: 2026: 12 · 2025: 28 · 2024: 36 · 2023: 92 · 2022: 198 · 2021: 476 · 2020: 177
FWCI: 30.93
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: McCarthy Family Foundation
AIDS Healthcare Foundation (Grant to OOY)
National Institutes of National Institute of Allergy and Infectious Diseases (AI124979, AI131879, AI140775, UM1AI068616, UM1AI068632, UM1AI106716)
Doris Duke Charitable Foundation (2019086)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Mental Health
James B. Pendleton Charitable Trust
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords: SARS-CoV-2, COVID-19 pandemic, antibody persistence, anti-spike antibodies, receptor binding domain, mild COVID-19, antibody waning
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Antibodies, Viral, Female, Humans, Immunoglobulin G, Male, Middle Aged, Pneumonia, Viral, Coronavirus Infections, Young Adult, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks